Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)

被引：0
|
作者：
Sayala, HA
Moreton, P
Jones, RA
Rawstron, AC
O'Connor, SJ
Evans, P
Carter, A
Dearden, C
Matutes, E
Pettitt, AR
Kennedy, DB
Hillmen, P
机构：
[1] Leeds Gen Infirm, HMDS, Leeds, W Yorkshire, England
[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
[3] Inst Canc Res, Haematooncol Dept, London SW3 6JB, England
[4] Leicester Royal Infirm, Dept Haematol, Leicester, Leics, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [11] Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group
    Elter, T.
    James, R.
    Wendtner, C. M.
    Stilgenbauer, S.
    Winkler, D.
    Ritgen, M.
    Hallek, M.
    Engert, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [12] Phase II Trial of Subcutaneous Alemtuzumab in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 202 - 203
  • [13] Subcutaneous alemtuzumab in patients with refractory/relapsed B-cell CLL after a fludarabine-based regimen. An interim analysis.
    Bezares, R. Fernando
    Stemmelin, German
    Argentieri, Daniel
    Lanari, Emilio
    Guy-Garay, Efrain
    Campestri, Reinaldo
    Bartomioli, Miguel
    Garcia, Juan Jose
    Giralt, Sergio
    Milone, Gustav
    BLOOD, 2006, 108 (11) : 805A - 805A
  • [14] Fludarabine versus fludarabine plus cyclophosphamide as first line therapy of advanced chronic lymphocytic leukemia (CLL):: First interim analysis of a phase III study (CLL4 protocol) of the German CLL study group (GCLLSG).
    Schmitt, BF
    Bergmann, M
    Busch, R
    Wendtner, CM
    Pasold, R
    Anders, O
    Sezer, O
    Hurtz, HJ
    Söling, U
    Steinbrecher, C
    Emmerich, B
    Hallek, M
    BLOOD, 2001, 98 (11) : 633A - 633A
  • [15] Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL:: CLL2H study of the German CLL Study Group (GCLLSG)
    Stilgenbauer, S
    Kröber, A
    Winkler, D
    Kienle, D
    Busch, R
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    ANNALS OF ONCOLOGY, 2005, 16 : 43 - 43
  • [16] Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia, (CLL):: results of a phase II study of the German CLL Study Group
    Hallek, M
    Schmitt, B
    Wilhelm, M
    Busch, R
    Kröber, A
    Fostitsch, HP
    Sezer, O
    Herold, M
    Knauf, W
    Wendtner, CM
    Kuse, R
    Freund, M
    Franke, A
    Schriever, F
    Nerl, C
    Döhner, H
    Thiel, E
    Hiddemann, W
    Brittinger, G
    Emmerich, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) : 342 - 348
  • [17] Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p-or Refractory to Fludarabine - Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW
    Stilgenbauer, Stephan
    Cymbalista, Florence
    Leblond, Veronique
    Delmer, Alain
    Zenz, Thorsten
    Winkler, Dirk
    Buehler, Andreas
    Mack, Silja
    Busch, Raymonde
    Ibach, Stefan
    Choquet, Sylvain
    Dartigeas, Caroline
    Cazin, Bruno
    Tournilhac, Olivier
    Rieger, Michael
    Soekler, Martin
    Seiler, Till
    Schetelig, Johannes
    Dreger, Peter
    Hallek, Michael
    Doehner, Hartmut
    BLOOD, 2010, 116 (21) : 406 - 406
  • [18] Phase II study of talabostat and rituximab in fludarabine/rituximab-resistant or refractory patients with CLL.
    Khan, K. D.
    O'Brien, S.
    Rai, K. R.
    Brown, J. R.
    Abboud, C.
    Hurd, D. D.
    Conkling, P.
    Yang, Z.
    Haltom, E. J.
    Uprichard, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [19] Phase II trial of the diphtheria fusion protein ONTAK in patients with fludarabine refractory chronic lymphocytic leukemia (CLL).
    Frankel, AE
    Patrick, CL
    Powell, BL
    BLOOD, 2001, 98 (11) : 289B - 289B
  • [20] CHOP plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune hemolytic anemia (AIHA) or Richter's transformation (RT): First interim analysis of a phase II trial of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Duehrsen, U
    Schulz, H
    Wendtner, CM
    Goebeler, ME
    Hallek, M
    BLOOD, 2005, 106 (11) : 601A - 601A
12345